Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
So lots of posters and and presentations this morning, but not a lot of actionable information for patients (as far a we could tell). Among the more interesting papers were the following:
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: Gleason score, MDV3100, mortality, OGX-011, positive, risk, surgical. margin | Leave a Comment »
A story in Science Daily, based on new article in the Proceedings of the National Academy of Sciences (PNAS) , has suggested that blood levels of “prostasomes” may be a more accurate marker for prostate cancer risk that PSA levels in blood.
Filed under: Diagnosis, Management, Risk | Tagged: Diagnosis, Gleason score, marker, protasome | 1 Comment »
A research group at Memorial Sloan-Kettering Cancer Center has published data indicating that translocation and/or deletion of the TMPRSS2-ERG fusion gene — which occurs in about 50 percent of the cases of clinically localized prostate cancer — is not, in fact, a prognostic indicator of risk for a more aggressive type of disease.
Filed under: Diagnosis, Risk | Tagged: deletion, gene fusion, Gleason score, TMPRSSG2-ERG, translocation | Leave a Comment »
A recently published Italian study has reported on whether perineural invasion (PNI) has prognostic value in patients undergoing radical prostatectomy for organ-confined prostate cancer, and on its possible correlation with other recognized prognostic factors.
Filed under: Management, Treatment | Tagged: Gleason score, outcome, perineural invasion, PNI, prognosis, stage | 14 Comments »
A new article from a group in the UK suggests that there is no difference in outcomes between patients with localized disease and with Gleason scores of 4 + 3 = 7 or 3 + 4 = 7 when their PSA is ≤ 10 and they are treated with iodine-125-based, permanent seed brachytherapy.
Filed under: Management, Treatment | Tagged: brachytherapy, Gleason score, localized, outcome | Leave a Comment »
There have been a number of interesting reports over the past couple of days that are summarized briefly below. They encompass such topics as: The validity of the Epstein criteria in predicting clinically indolent prostate cancer MRI and MRSI in patient work-up prior to treatment for stage T1c disease Contrast-enhanced, color Döppler ultrasound and prostate [...]
Filed under: Uncategorized | Tagged: ADT, age, androgen deprivation therapy, color Döppler, comorbidities, Epsetin criteria, Gleason score, magnetic resonance, mortality, MRI, MRSI, testosterone, ultrasound, unilateral | 2 Comments »
Three reports discussed today address the refinement of risk information in the diagnosis and prognosis of prostate cancer, with specific regard to: Whether PSA levels should be adjusted based on BMI The prediction of Gleason score upstaging after surgery Tumor volume and percent cancer as predictors of prostate cancer progression post-surgery
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: BMI, Gleason score, obesity, percent cancer, PSA, tunor volume, upstaging | Leave a Comment »
Several reports have clearly shown that biochemical recurrence (a rising PSA) after first-line treatment is more common among men with a Gleason score of 4 + 3 = 7 than it is in men with a Gleason score of 3 + 4 = 7. However, there has been no confirmation of an association between these [...]
Filed under: Living with Prostate Cancer | Tagged: Gleason score, prostate cancer-specific survival | 31 Comments »
Today’s prostate cancer news reports cover items on: Assessment of quality of life after radical prostatectomy Permanent seed brachytherapy in treatment of localized disease Cryotherapy in treatment of patients with Gleason 8-10 localized disease Actonel and/or estradiol in prevention of SREs
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: Actonel, brachytherapy, cryotherapy, estradiol, Gleason score, outcome, permanent, quality of life, risedronate, seed, survey | Leave a Comment »
In today’s news reports we cover items on: Prediction of risk for prostate cancer under-grading based on biopsy data The obesity/risk equation in prostate cancer Capecitabine + docetaxel in metastatic CRPC
Filed under: Diagnosis, Drugs in development, Management, Risk, Treatment | Tagged: biopsy, capecitabine, CRPC, docetaxel, Gleason score, obesity, risk, under-grading | Leave a Comment »
The following four reports address some other interesting papers and posters presented at the AUA today.
Filed under: Management, Treatment | Tagged: active surveillance, dosing, Epsetins's criteria, Gleason score, LHRH therapy, positive surgical margins | Leave a Comment »
Today’s news reports contain four key items: A review of the potential of phytochemicals in treatment of prostate cancer A Norwegian study on correlation between biopsy-based and post-surgical Gleason scores A retrospective study on risk for prostate cancer in men being treated with testosterone replacement therapy An announcement of new data on PSP94 in the [...]
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: biopsy, Gleason score, Miraculins, phytochemicals, PSP94, testosterone replacement, TRT | Leave a Comment »
In addition to the comentary on outcomes of radical prostatectomy in men of 70 years and older, there are four reports in today’s news, addressing: Garlic as a dietary component that prevents cancer How “knock down” of androgen receptor expression and PCPH expression may potentially impact prostate cancer treatment The clinical impact of discordant post-biopsy and [...]
Filed under: Drugs in development, Management, Treatment | Tagged: discordance, garlic, gene expression, Gleason score, knock down | Leave a Comment »
We have separately addressed a report on 10-year outcome data following (non-robotic) laparoscopic radical prostatectomy for localized prostate cancer. In today’s other reports we have addressed: The potential of annexin A3 as a marker for early diagnosis of prostate cancer The ability of PSAV and PSAD to predict risk for prostate cancer in men with one or [...]
Filed under: Diagnosis, Management, Treatment | Tagged: annexin, estogen, Gleason score, marker, PSA density, PSA velocity, receptor | Leave a Comment »
Today’s news items address such matters as: The potential importance of the “new” (International Society of Urological Pathology) rules for reporting Gleason scores Post-operative surgical outcomes among African Americans Post-brachytherapy outcomes and exposure to Agent Orange “Masculinity” and prostate cancer treatment among low income African Americans and Latinos The adverse effects of ADT among elderly [...]
Filed under: Diagnosis, Management, Treatment | Tagged: ADT, African American, Agent Orange, Gleason score, Latino | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site